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ABSTRACT
Objective We prospectively determined islet
autoantibody status in children presenting with diabetes
to a single UK region in relation to ethnicity.
Design 316 (68.0% non-white) children presenting
with diabetes between 2006 and 2013 were tested
centrally for islet cell autoantibodies (ICA) and glutamic
acid decarboxylase autoantibodies (GAD-65) at
diagnosis, and if negative for both, tested for insulin
autoantibodies (IAA). The assay used to measure
GAD-65 autoantibodies changed from an in-house to a
standardised ELISA method during the study.
Results Even with use of the standardised ELISA
method, 25.8% of children assigned a diagnosis of type
1 diabetes still tested negative for all three
autoantibodies. 30% of children assigned a diagnosis of
type 2 diabetes were autoantibody positive, and these
had the highest glycated haemoglobin (HbA1c) levels at
12 months follow-up compared with other groups (p
value for analysis of variance <0.001), although the
sample size was small. Autoantibody positivity was
similar between non-white and white children regardless
of assay used (60.0% (n=129) vs 56.4% (n=57),
χ2=0.9, p=0.35), as was mean GAD-65 autoantibody
levels, but fewer non-white children had two or more
autoantibodies detectable (13% (n=28) vs 27.7%
(n=28), χ2=12.1, p=0.001).
Conclusions Islet autoantibody positivity was
associated with a more severe phenotype, as
demonstrated by poorer glycaemic control, regardless of
assigned diabetes subtype. Positivity did not differ by
ethnic group.
INTRODUCTION
The UK National Diabetes Audit shows that 9% of
adults have type 1A diabetes (T1D), with most of
the remainder registered as having type 2 diabetes
(T2D).1 For T1D compared with T2D adult popula-
tions, risk of vascular complications, intermediate
outcomes and years of life lost are greater and treat-
ment targets are less likely to be achieved.2 Given
these adult outcomes, the possible effect of obesity
on presentation with diabetes,3 and future prospects
for interventions to preserve beta-cell function,4 it is
increasingly important for paediatric diabetes practi-
tioners to clearly deﬁne diabetes subtype for a child
presenting with diabetes and align relevant care pro-
cesses and treatments accordingly.
Islet autoantibodies are important markers of
T1D-associated autoimmunity.4 However, the UK
Prospective Diabetes Study (UKPDS) showed that
12% of adults with T2D in this trial tested positive
for islet autoantibodies, and this was associated with
increased future risk of requiring insulin.5 In a clinic
setting, the latest UK National Paediatric Diabetes
Audit shows that 96.4% and 1.3% of children and
young persons have been assigned a diagnosis of
T1D and T2D, respectively.1 Yet, with more detailed
investigation, the landmark US SEARCH study
showed that 54.5% of young people had an auto-
immune plus insulin-sensitive (IS) phenotype consist-
ent with T1D, and 15.9% had a non-autoimmune
insulin-resistant (IR) phenotype, consistent with
T2D,6 with the remainder having a mixed pheno-
type. In addition, there was evidence of ethnic differ-
ences in islet positivity during SEARCH: fewer
non-white children (mostly Hispanic and
Afro-American) had an autoimmune IS phenotype,
and more had a non-autoimmune IR phenotype.6 In
a separate US study, Libman et al7 found that black
children were less likely to have autoantibodies.
We determined islet autoantibody status in a
clinic setting in children and young persons from a
majority non-white (largely black African and
South Asian) region of inner London who pre-
sented with diabetes between 2006 and 2013.
METHODS
Patient selection
Our cohort consisted of children from two paediat-
ric diabetes centres (Queens Hospital in Romford
What is already known on this topic
▸ Previous studies in this ﬁeld, largely from the
USA, indicate high prevalence of islet
autoantibody positivity in children with a
diagnosis of type 2 diabetes.
▸ The same studies demonstrate ethnic
differences in islet autoantibody status.
What this study adds
▸ This is the ﬁrst report from a contemporary UK
paediatric diabetes clinic setting of islet
autoantibody status in relation to clinical
phenotype.
▸ Children and young people assigned a
diagnosis of type 2 diabetes who are islet
autoantibody positive have the poorest
glycaemic control.
▸ In contrast with US studies, islet autoantibody
positivity did not differ by ethnicity.
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and The Royal London Hospital) diagnosed with diabetes
between January 2006 and April 2013 by specialist paediatric
diabetes practitioners and aged <19 years. A diagnosis of T1D
was assigned according to American Diabetes Association and
International Society for Paediatric and Adolescent Diabetes
guidelines after careful consideration by a paediatric diabetolo-
gist of the clinical presentation, biochemical abnormalities, the
need for insulin and the total daily insulin dose, and the pres-
ence of islet autoantibodies.8 9 The diagnosis was reconsidered
in light of symptoms and signs of a rarer form of diabetes (in
which case genetic mutation analysis for monogenic diabetes
was requested). If a child had negative islet autoantibody status,
then a diagnosis of T1D was unaltered in the absence of other
symptoms and signs—for example, insulin resistance or syn-
dromic features. Diagnosis of T2D was considered in the pres-
ence of obesity, a family history of T2D and evidence of insulin
resistance clinically (acanthosis nigricans), biochemically
(normal or raised insulin and C-peptide levels during fasting or
an oral glucose tolerance test and outside of the honeymoon
period) and therapeutically (daily insulin requirements >1.5
units/kg and signiﬁcant response to oral hypoglycaemic agents).
Islet autoantibody status only became known at the following,
usually the ﬁrst, clinic appointment. Clinical and demographic
data were prospectively collected during clinic visits and entered
on to a dedicated diabetes database. Ethnicity was self-reported
and coded according to the UK Ofﬁce of National Statistics
2010 census guidelines.10 For this study, children and young
persons were grouped into three categories: white, South Asian
and black (migrants to the UK of black African descent). Ethics
committee approval was not sought because no interventions
were performed for the purpose of the study.
Assays
Blood samples for measurement of autoantibodies were col-
lected by venepuncture at initial presentation, allowed to clot,
and the serum separated as soon as possible to prevent haemoly-
sis. Serum was stored at 2–8°C. Blood samples were processed
centrally at the immunology department at the Royal London
Hospital and recorded electronically. The department operated
a test selection policy whereby initially only islet cell antibodies
(ICA) and glutamic acid decarboxylase (GAD-65) autoantibodies
are measured, and, if these were negative, then insulin autoanti-
bodies (IAA) were measured. A patient was considered autoanti-
body positive if at least one autoantibody was positive.
Before July 2007, samples were sent to the Protein Reference
Unit at Shefﬁeld, who used their in-house ELISA method for
GAD-65 autoantibody measurement.11
Indirect immunoﬂuorescence: GAD-65 antibodies
From August 2007 to December 2011, GAD-65 autoantibodies
were measured using an indirect immunoﬂuorescence technique.
Samples were screened for GAD-65 antibodies using commercial
monkey cerebellum slides12 (Instrumentation Laboratory Limited,
UK) at a 1:10 dilution. The secondary antibody used was a monkey
adsorbed ﬂuorescein isothiocyanate (FITC)-conjugated polyclonal
rabbit anti-human IgG (Instrumentation Laboratory Limited). Slides
were viewed using a ﬂuorescence microscope. Positive samples pro-
duced an apple-green ﬂuorescence in the cytoplasm in the molecular
layer, together with a less intense and patchy staining of the nerve
terminals in the granular layer. Nuclei and glial cells are negative.
ELISA: GAD-65 antibodies
Since January 2012, sera were tested using a GAD-65 autoanti-
body (GAD-65) ELISA kit (RSR, UK).13 The wells of the
microtitre plate were coated in a full-length human recombinant
GAD-65. Any antibodies directed against any GAD-65 antigens
present in the serum were bound to the microtitre plate. After a
wash step, GAD biotin was added in a further incubation step,
and a bridge formed between the GAD immobilised on the plate
and the GAD biotin. The amount of GAD biotin bound is then
determined by adding streptavidin peroxidase, which hydrolyses
a chromogenic substrate (3,30,5,50-tetramethylbenzidine) to give
a colour change. Acid was used to stop the reaction, and the
intensity of colour was measured photometrically (450 and
405 nm).
Indirect immunoﬂuorescence for ICA
ICA were tested for using commercial monkey pancreas slides14
(Instrumentation Laboratory Limited) at a 1:2 dilution. The sec-
ondary antibody used was an FITC polyclonal rabbit anti-
human IgG (Dako, UK). The slides were observed under a ﬂuor-
escence microscope, and a sample was designated positive if the
cytoplasm of all the islet cells was stained.
Fluorescence enzyme immunoassay for IAA
Samples that were negative for both ICA and GAD-65 autoanti-
bodies were sent to the Protein Reference Unit at Shefﬁeld for
IAA testing, using ﬂuorescence enzyme immunoassay on the
Phadia250 (Thermo Scientiﬁc). It uses their ImmunoCAP
Speciﬁc IgG methodology and is designed as a sandwich
immunoassay. The insulin antigen, covalently coupled to the
solid phase, reacts with any speciﬁc IgG antibodies present in
the patient sample. After washing away of non-speciﬁc IgG anti-
bodies, enzyme-labelled antibodies against IgG are added to
form a complex. After incubation and a wash step, the bound
complex is then incubated with a developing agent. After the
reaction is stopped, the ﬂuorescence of the eluate is measured.
The higher the ﬂuorescence, the more speciﬁc IgG antibodies
are present in the sample. A cut-off of 5 mg/L was established
following an internal evaluation and audit by the Protein
Reference Unit.
Statistical analysis
Information on islet autoantibody status on the diabetes data-
base was validated against results from the centralised immun-
ology department electronic database at the Royal London
Hospital. Given potential concerns that the assay method for
measuring GAD-65 autoantibodies varied over three different
time periods, for individuals assigned a diagnosis of T1D, we
included data from any time point if they tested autoantibody
positive. Those with T1D who tested autoantibody negative in
the time periods up to January 2012 were excluded from ana-
lysis because of the limitations of the assays used to measure
GAD-65 autoantibodies before this time —that is, for the ana-
lysis, T1D autoantibody-negative individuals were only from the
time period after January 2012 as this is when the standardised
GAD-65 autoantibody assay was used. Data on clinical and bio-
chemical variables were summarised as means and compared
between the four independent groups using a Student t test or
analysis of variance (ANOVA) model and by the χ2 test. For
ANOVA testing, all variables were normally distributed, and we
tested differences in variance between the four groups. SPSS
V.16.1 was used for all analysis. A p value <0.05 was taken as
signiﬁcant.
RESULTS
Between January 2006 and April 2013, 316 children with dia-
betes had two or more islet autoantibody levels measured at
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diagnosis. Of these, 296 (93.7%) were assigned a diagnosis of
T1D, and the remainder were assigned a diagnosis of T2D. The
latter group were all prescribed metformin therapy, and ﬁve
were on once daily insulin glargine.
Islet autoantibody status
From 316 children presenting with diabetes during the study
period, 192 (60.8%) tested positive for any islet autoantibody
using any assay. Median time from diagnosis of diabetes to islet
autoantibody testing was 0.1 years (range 0–0.7). During the
three time periods when the GAD-65 autoantibody assay
changed from an in-house ELISA method (before July 2007) to
an indirect immunoﬂuorescence method (August 2007 to
December 2011) and then a standardised RSR ELISA method
(from January 2012), the frequency of GAD-65 positivity
increased signiﬁcantly and hence the frequency of children
testing positive for any autoantibody increased (table 1). Mean
GAD antibody levels for those who tested positive were 477.9
units/mL (SD 714.6).
We then compared the phenotype according to the assigned
diabetes subtype and islet autoantibody status by dividing the
cohort into four groups; T2D±autoantibody positivity and
T1D±autoantibody positivity (the T1D autoantibody-negative
group was restricted to those who tested negative after January
2012 as discussed in the methods, n=68).
Even with use of the standardised ELISA method for meas-
urement of GAD-65 autoantibody, 25.8% of children assigned a
diagnosis of T1D still tested negative for all three autoantibodies
(table 1), but no differences in phenotype were observed when
compared with autoantibody-positive T1D children (table 2).
Children assigned a diagnosis of T2D were older at presenta-
tion and heavier than those with T1D. Some 30% were autoanti-
body positive, and these had higher HbA1c at follow-up and
body mass index (BMI) SD scores (SDSs) than the remainder of
the cohort (table 2 and ﬁgure 1). Owing to the small sample, we
were unable to evaluate any differences in insulin requirements.
There was no association with age and number of islet
autoantibodies measured and the number of islet autoantibodies
that tested positive. In addition, there was no association with
age and islet autoantibodies positivity by ethnicity.
Ethnicity
Non-white children had a greater BMI SDS than white children
(0.8 (1.9) vs 0.4 (1.4), p=0.001). In non-white (215 from 316,
68.0%) versus white children, ICA positivity was 38.1% vs
50.6% (χ2=3.4, p=0.06) and IAA positivity was 24.0% vs
25.5% (χ2=1.1, p=0.66). GAD-65 positivity was 13.2% vs
36.4% (χ2=3.1, p=0.09) before July 2007 using the in-house
ELISA method, 14.4% vs 12.1% (χ2= 1.3, p=0.49) between
August 2007 and December 2011 using indirect immunoﬂuores-
cence, and 67% vs 65% (χ2=0.7, p=0.84) after January 2012
using the standardised ELISA method. Mean GAD-65 antibody
levels for those who tested positive for GAD-65 did not differ
by ethnicity (non-white vs white; 345.1 (690.3) vs 309.5
(602.1) units/mL, p=0.84). Overall autoantibody positivity
during the study period was similar between non-white and
white children (60.0% (n=129) vs 56.4% (n=57), χ2=0.9,
p=0.35), but fewer non-white children had two or more auto-
antibodies detectable (13% (n=28) vs 27.7% (n=28), χ2=12.1,
p=0.001). HbA1c levels did not differ by autoantibody status in
Table 1 Islet autoantibody status during changes in GAD-65 autoantibody assay methods
Before July 2007 August 2007–December 2011 After January 2012 p Value
Sample size (T1D/T2D) 81 (77/4) 167 (157/10) 68 (62/6) 0.61
GAD-65 assay In house ELISA Indirect immunofluorescence Standardised ELISA
GAD-65 +ve (%) 18.4 13.8 66.7 <0.001
ICA +ve (%) 50.6 38.2 45.0 0.18
IAA +ve (%) 26.5 24.0 21.9 0.88
Positivity for any antibody (%) 64.6 49.1 72.2 0.002
T2D with antibody positivity (%) 50.0 10.0 50.0 0.2
T1D with antibody negativity (%) 32.4 44.2 25.8 0.09
IAA, insulin autoantibody; ICA, islet cell autoantibody; GAD, glutamic acid decarboxylase; T1D, type 1A diabetes; T2D, type 2 diabetes.
Table 2 Phenotype in relation to diabetes subtype and islet autoantibody status
T2D antibody +ve
(n=6) (1.9%)
T1D antibody –ve
(n=16) (25.8%)
T1D antibody +ve
(n=186) (59.1%)
T2D antibody –ve
(n=14) (4.4%)
p Value for
ANOVA
Non-white, n (%) 4 (66.7) 12 (75.0) 139 (74.7) 11 (79) 0.45
Age at diagnosis of diabetes (years) 12.5 (3.7) 10.6 (4.6) 9.1 (4.3) 14.1 (1.7) <0.001
Duration of diabetes (years) 2.1 (2.6) 0.6 (0.3) 1.9 (2.3) 1.6 (1.8) 0.15
HbA1c at diagnosis, % (SD)mmol/mol 10.6 (2.3)
92
9.7 (3.6)
83
9.6 (2.2)
81
8.0 (2.4)
64
0.03
HbA1c 12 months after diagnosis, %
(SD)mmol/mol
9.7 (2.2)
8.3
6.9 (1.3)
52
8.7 (1.7)
72
9.4 (2.7)
79
<0.001
BMI SDS at presentation 2.0 (2.2) 0.6 (1.4) 0.7 (1.6) 1.5 (1.7) <0.001
On insulin treatment, n (%) 1 (16.7) 16 (100) 186 (100) 5 (35.7) 0.22
The T1D autoantibody-negative group was restricted to those who tested negative after January 2012, as this is when the standardised RSR ELISA method for GAD-65 autoantibody
measurement was used —that is, T1D-negative children diagnosed before January 2012 were excluded.
Unless otherwise noted, values are mean (SD).
BMI, body mass index; HbA1c, glycated haemoglobin; SDS, standard deviation score; T1D, type 1A diabetes; T2D, type 2 diabetes.
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the three ethnic groups. There were more girls in the non-white
group (n=121 (62%) vs n=48 (40%), p<0.001), but no gender
differences were found in autoantibody status. No differences were
observed within ethnic groups (black African and South Asian).
DISCUSSION
In this multi-ethnic UK clinic cohort of childhood-onset diabetes,
we aimed to determine the percentage of children assigned a
diagnosis of T1D or T2D who tested positive for at least one
autoantibody. Despite use of a standardised ELISA method for
GAD-65 autoantibody, 25.8% of children assigned a diagnosis of
T1D still tested negative for all three autoantibodies, but no
phenotypic difference existed in these compared with
autoantibody-positive T1D children. Some 30% of children
assigned a diagnosis of T2D were autoantibody positive, and
these had the highest HbA1c at the 12-month follow-up (p value
for ANOVA <0.001) and BMI (p value for ANOVA <0.001).
We found no overall difference in rates of autoantibody positivity
between ethnic groups at presentation with diabetes.
Studies that have added to our knowledge of the phenotype of
children presenting with diabetes include the landmark US
SEARCH6 and TODAY Studies,15 a study in German and Austrian
youths,16 and the Childhood Diabetes in Finland Study.17 The
TODAYand German/Austrian studies were limited to patients with
T2D. Certain observations from these studies are relevant to our
study. First, rate of islet autoantibody positivity appears to differ
between studies—for example, during SEARCH, only 38% of
individuals were positive for both IAA and GAD-65 autoanti-
body,6 but during the Finnish Study, 91% tested positive for both
autoantibodies.18 Second, 15.1% of T1D children were autoanti-
body negative during SEARCH compared with 25.8% in our
study, and this may reﬂect differences in assay standardisation,
number of autoantibodies measured and population between
studies. Other major islet autoantibody markers of T1D include
zinc transporter 8 and IA2.18 Routine measurement of these auto-
antibodies in the immediate period after diagnosis increases the
rate of autoantibody positivity.19 Third, differences exist in rates
of autoantibody-positive T2D children between studies: 12.6%,
9.8% and 15% of T2D children were autoantibody positive
during the SEARCH, TODAY and German/Austrian studies,
respectively, compared with 30% in our UK clinic cohort.6 15 16
This may reﬂect differences in criteria for diabetes classiﬁcation,
ethnicity and the other reasons mentioned above. We found that
autoantibody-positive T2D children had the highest HbA1c at the
12-month follow-up and BMI, suggesting a more severe pheno-
type. This is consistent with observations from SEARCH, where
similar children had lower C-peptide levels and higher BMI,6 and
from TODAY where similar children had the highest HbA1c level
and lowest C-peptide.6 Finally, there was evidence of ethnic differ-
ences in autoantibody status in the SEARCH and TODAY studies.
During SEARCH, more non-Hispanic white children were auto-
antibody positive compared with other ethnic groups. During
TODAY, more non-Hispanic white T2D children were autoanti-
body positive, compared with other ethnic groups.15 In the
German and Austrian study of youth with T2D, positivity was not
compared between ethnicities. Our study found similar positivity
between white, Asian and Black ethnic groups. These inconsistent
outcomes require further investigation.
Although controversial, the blurred clinical distinction between
T1D and T2D may be related to the increasing prevalence of
obesity,20 but the impact this has on the natural history of diabetes
is unclear.21 In adults with diabetes, it is unclear whether knowl-
edge of islet autoantibody status changes management; evidence
that positivity predicts insulin requirements in T2D in the UKPDS
was based on a small sample size, and overall accuracy of the pre-
diction was low and did not inﬂuence HbA1c response to medica-
tion22 or rates of diabetic ketoacidosis.23 Similarly, in childhood
epidemiological studies, islet positivity did not predict insulin
requirements in patients with T2D.24 25 However, other data indi-
cate a link between islet autoantibody status and decline in beta-
cell function,26 and, during euglycaemic clamps, children with
islet autoantibody positivity and obesity have lower insulin levels27
and increased cardiovascular risk factors.28 Consistent with this,
both the SEARCH and TODAY studies and, to a lesser extent, our
study indicate a more severe phenotype in relation to autoimmune
status.6 15 As yet, it is unclear whether early introduction of insulin
therapy may be beneﬁcial, and this requires further study.
Limitations of the study
Our sample size was small, and we did not have C-peptide mea-
surements, HLA genotyping, measurements of insulin sensitivity
or deep clinical phenotype to support some of our observations.
It is likely that diagnostic accuracy may have changed over time;
however, the same diagnostic criteria were applied to each
patient throughout the study by the same physicians.
Limitations of the assays
The sensitivity and speciﬁcity for ICA indirect immunoﬂuores-
cence are 85% and 98%, and for GAD ELISA testing are 92%
(n=50) and 98% (n=100), respectively. The GAD ELISA has a
cut-off of ≤5 U/mL and a lower detection rate at +2SDs of
0.57 U/mL. The interassay precision of the kit has been shown to
have a coefﬁcient of variation of 5.7% with a sample of 96.9 U/
mL and 5.2% for a sample of 21.0 U/mL (n=20). The intra-assay
precision was 7.3% for a sample of 97.2 U/mL and 8.5% for a
sample of 20.0 U/mL (n=25). Indirect immunoﬂuorescence was
the method used to test GAD-65 autoantibodies between August
2007 and December 2011. This method relies on a subjective
assessment of the slides under a microscope, and is therefore
subject to operator error. However, the results were always
Figure 1 Glycated haemoglobin (HbA1c) levels (±SE) at diagnosis in
relation to diabetes subtype and islet autoantibody status. The T1D
autoantibody-negative group was restricted to those who tested
negative after January 2012, as this is when the standardised RSR
ELISA method for GAD-65 autoantibody measurement was used—that
is, T1D-negative children diagnosed before January 2012 were
excluded. Ab, antibody; ANOVA, analysis of variance; T1D, type 1A
diabetes; T2D, type 2 diabetes.
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checked by a second operator, and, if there were any equivocal
results, then the test was repeated. The laboratory also carried out
monthly screening audits whereby known antibody-positive or
-negative samples, including ICA and GAD autoantibodies, were
tested and read by all screeners to ensure consistency in interpret-
ation, and results were analysed, fed back and discussed. Another
consideration is that the ﬁlters and optics of the microscope will
inﬂuence the sensitivity of the kit,12 but this was minimised by
regular testing and maintenance of the microscope. A recognised
limitation of ICA testing with immunoﬂuorescence is the potential
for another autoantibody, such as anti-nuclear antibody or anti-
mitochondrial antibody, to hide or be confused with GAD-65.
This could potentially also be relevant for GAD-65 autoantibody
testing with immunoﬂuorescence.14 These factors may have inﬂu-
enced our lower sensitivity for GAD-65 autoantibodies using indir-
ect immunoﬂuorescence compared with ELISA. All test methods
would be run with internal quality controls and the testing labora-
tory would be Clinical Pathology Accredited accredited and partici-
pate in national external quality assurance (NEQAS), which
highlights any issues with the laboratory processes or test proto-
cols/methods. However, these controls and NEQAS samples
would, in the majority of cases at least, be using adult sera and may
not always be relevant in the paediatric population.
Conclusions
This is the ﬁrst UK study to date that evaluates islet autoantibody
status and phenotype in relation to speciﬁc ethnic groups in a
cohort of both T1D and T2D children using information routinely
collected during clinic appointments. The effect of islet autoanti-
body status on disease progression is unclear in those assigned a
diagnosis of T2D and requires further study. Overall islet autoanti-
body positivity did not differ by ethnicity.
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